Compare PMAX & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMAX | SCNI |
|---|---|---|
| Founded | 2019 | 2003 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 4.6M |
| IPO Year | 2024 | N/A |
| Metric | PMAX | SCNI |
|---|---|---|
| Price | $3.31 | $1.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 42.2K |
| Earning Date | 09-23-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | ★ $4,799,100.00 | $1,147,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.55 |
| Revenue Growth | N/A | ★ 303.87 |
| 52 Week Low | $1.56 | $0.86 |
| 52 Week High | $25.44 | $6.18 |
| Indicator | PMAX | SCNI |
|---|---|---|
| Relative Strength Index (RSI) | 74.38 | 57.11 |
| Support Level | $1.56 | $0.99 |
| Resistance Level | $3.04 | $1.15 |
| Average True Range (ATR) | 0.29 | 0.09 |
| MACD | 0.16 | 0.04 |
| Stochastic Oscillator | 97.77 | 100.00 |
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.